Skip to main content
. Author manuscript; available in PMC: 2008 Jun 4.
Published in final edited form as: J Immunother. 2003;26(1):85–93. doi: 10.1097/00002371-200301000-00009

FIG. 1.

FIG. 1

CD4+CD25+ T cells are present in patients with melanoma. Cells were labeled with PE-conjugated CD25 antibody and FITC-conjugated CD4 antibody. Proper isotype controls were also done, but are not presented here. (A) CD4+CD25+ T cells represent a significant portion of total PBMC in patients with melanoma. CD4+CD25+ T cells were 16.6% (± 5.4, n = 20) of total PBMC and 34.2% (± 8.0, n = 20) of CD4+ T cells. (B) Moreover, using the MACS system by Miltenyi Biotec, CD4+CD25+ T cells were purified with 74% purity (SDEV = ± 16.8, n = 16) and CD4+CD25− T cells were purified with 74% purity (SDEV = ± 14.3, n = 16).